Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mixed bacteria vaccine
- Development stage
- Phase 1
- Lead developer
- William Coley
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Intramuscular, Oral, Sublingual
01
Overview
Mixed bacteria vaccine (MBV), also known as Coley's toxins, is a biological response modifier composed of a pyrogenic lysate derived from killed Streptococcus pyogenes and Serratia marcescens. Developed in the late 19th century by William Coley, it was originally used as an experimental immunotherapy for cancer. The active components are believed to include lipopolysaccharide (LPS) from the Gram-negative Serratia cell wall and streptokinase from Streptococcus. MBV stimulates immune responses, including production of interleukin-2 (IL-2), interferon (IFN), and tumor necrosis factor (TNF). Historically, it was administered via injection for cancer treatment and prevention of respiratory infections but has largely fallen out of use due to lack of proven efficacy and potential risks. More recently, oral or sublingual forms have been explored for preventing recurrent respiratory tract infections and asthma exacerbations[1][3][6].
- Brand names
- Vaccineurin
- Other names
- Coley's toxinsColey vaccineColey’s fluidmixed bacterial vaccine
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on mixed bacteria vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mixed bacteria vaccine.